Immunotherapy for platinum-resistant ovarian cancer

Bogani, Giorgio; Lopez, Salvatore; Mantiero, Mara; Ducceschi, Monika; Bosio, Sara; Ruisi, Simona; Sarpietro, Giuseppe; Guerrisi, Rocco; Brusadelli, Claudia; Dell’Acqua, A.; Donato, Violante Di; Raspagliesi, Francesco

doi:10.1016/j.ygyno.2020.05.681

Cited by 61 publications

(55 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OC is a malignant tumor with a poor prognosis and the leading mortality rate among gynecological malignancies (19,20). Despite significant advances in surgical treatments and chemotherapy in recent years, the survival rate for OC has improved only slightly (21,22). Several experimental and clinical studies have shown that immunotherapy has incomparable advantages over traditional anti-tumor therapies in terms of extending PFS and OS, especially in patients with advanced cancer (23,24).…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis

et al. 2021

View full text Add to dashboard Cite

Epithelial ovarian cancer has a low response rate to immunotherapy and a complex immune microenvironment that regulates its treatment outcomes. Understanding the immune microenvironment and its molecular basis is of great clinical significance in the effort to improve immunotherapy response and outcomes. To determine the characteristics of the immune microenvironment in ovarian cancer, we stratified ovarian cancer patients into three immune subtypes (C1, C2, and C3) using immune-related genes based on gene expression data from The Cancer Genome Atlas and found that these three subtypes had significant differences in immune characteristics and prognosis. Methylation and copy number variant analysis showed that the immune checkpoint genes that influenced immune response were significantly hypermethylated and highly deleted in the immunosuppressive C3 subtype, suggesting that epigenetic therapy may be able to reverse the efficacy of immunotherapy. In addition, the mutation frequencies of BRCA2 and CDK12 were significantly higher in the C2 subtype than in the other two subtypes, suggesting that mutation of DNA repair-related genes significantly affects the prognosis of ovarian cancer patients. Our study further elucidated the molecular characteristics of the immune microenvironment of ovarian cancer, which providing an effective hierarchical method for the immunotherapy of ovarian cancer patients, and has clinical relevance to the design of new immunotherapies and a reasonable combination strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…No mature evidence currently supports the adoption of immunotherapy in ovarian cancer patients [ 110 ]. Since CDK4/6i can profoundly impact on the immune response to different cancer types, it would be interesting to verify if the use of CDK4/6i may improve the efficacy of immune-checkpoint inhibitors, which would be particularly needed for platinum resistant patients that still have very few valid therapeutic options.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives

Dall'Acqua

Bartoletti

Masoudi-Khoram

et al. 2021

Cancers

View full text Add to dashboard Cite

Alterations in components of the cell-cycle machinery are present in essentially all tumor types. In particular, molecular alterations resulting in dysregulation of the G1 to S phase transition have been observed in almost all human tumors, including ovarian cancer. These alterations have been identified as potential therapeutic targets in several cancer types, thereby stimulating the development of small molecule inhibitors of the cyclin dependent kinases. Among these, CDK4 and CDK6 inhibitors confirmed in clinical trials that CDKs might indeed represent valid therapeutic targets in, at least some, types of cancer. CDK4 and CDK6 inhibitors are now used in clinic for the treatment of patients with estrogen receptor positive metastatic breast cancer and their clinical use is being tested in many other cancer types, alone or in combination with other agents. Here, we review the role of CDK4 and CDK6 complexes in ovarian cancer and propose the possible use of their inhibitors in the treatment of ovarian cancer patients with different types and stages of disease.

show abstract

“…Some studies have shown the severity and impact of cancer according to geographical regions using MIR, such as the states of a country. [13][14][15][16] Although Mexico has not been among the countries with the highest rates of LOCC in the world 17 or in the Latin American region, 18 the different presence of the main known risk factors between the sexes, 19 the latent influence of other factors of viral origin, 20 and the constant changes in social conditions that have been reflected in widely applied indicators such as the Human Development Index (HDI), [21][22][23] make it relevant to know how these associations have been according to the most recent data available. To our knowledge, LOCC has not been studied at the state level and by sex in Mexico.…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 99%

Effect of Human Development Index and other socioeconomic factors on mortality-to-incidence ratio of lips and oral cavity cancer in Mexican states: an ecological study

et al. 2021

View full text Add to dashboard Cite

ObjectivesTo assess the association between the Human Development Index (HDI) and covariates on the mortality-to-incidence ratio (MIR) of lips and oral cavity cancer (LOCC) in Mexico.DesignEcological study.SettingData from 32 Mexican states for year 2019.ParticipantsData set of male and female populations from Mexico.ExposuresSocioeconomic conditions based on HDI and covariates related to healthcare system capacity (total health spending per capita, school dropout and ratio of medical personnel in direct contact with patients).Primary and secondary outcome measuresMIR of LOCC by state and sex was calculated from the Global Burden of Disease Study website for year 2019. Data for calculating HDI 2019 by state and covariates were obtained from the National Institute of Statistics and Geography. A multiple regression model was constructed to measure the effects of HDI and covariates on LOCC-MIR.ResultsAmong the states with the highest HDI (>0.780), Colima had the highest aged-standardised rates per 100.000 in men for incidence (5.026) and mortality (3.118). The greatest burden of the disease was found on men, with the highest Men:Women MIR in Colima (3.10) and Baja California Sur (2.73). The highest MIR (>0.65) was found among the states with the lowest HDI (Oaxaca and Chiapas). For each unit of increase of the HDI there was a decrease in the LOCC- MIR of −0.778, controlling for the covariates. The most suitable regression model explained the 57% (F (p): 0.000) of the variance.ConclusionsMen were most affected by LOCC in Mexican states. The highest MIRs of LOCC were found in the states with the highest HDI. But a worse prognosis of the disease, expressed as a higher MIR, is expected in contexts with lower HDI in the country, even with lower MIRs.

show abstract

Immunotherapy for platinum-resistant ovarian cancer

Cited by 61 publications

References 42 publications

Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis

Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis

Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives

Effect of Human Development Index and other socioeconomic factors on mortality-to-incidence ratio of lips and oral cavity cancer in Mexican states: an ecological study

Contact Info

Product

Resources

About